--- title: "Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm" type: "News" locale: "en" url: "https://longbridge.com/en/news/293395330.md" description: "Kuehn Law, PLLC is investigating whether Regenxbio, Inc. officers and directors breached fiduciary duties by providing false or misleading information regarding the efficacy and safety of its RGX-111 gene therapy trial. The firm encourages shareholders who purchased RGNX prior to February 9, 2022, to contact them to potentially join a federal securities lawsuit." datetime: "2026-07-21T23:29:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/293395330.md) - [en](https://longbridge.com/en/news/293395330.md) - [zh-HK](https://longbridge.com/zh-HK/news/293395330.md) generator: "portal-rs" --- # Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm NEW YORK, July 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of **Regenxbio, Inc. ()** breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Regenxbio, Inc. provided investors with false and/or misleading information regarding the efficacy and safety of its trial study for RGX-111, a one-time gene therapy for the treatment of Hurler Syndrome, including positive assertions of RGX-111's future trial success based on continuing positive biomarker and safety data from the ongoing PhaseI/II study. If you currently own RGNX **and purchased prior to February 9, 2022** please contact Sophia Anne Silayan by email at sophiaanne@kuehn.law or call (833) 672-0814. **Kuehn Law pays all case costs and does not charge its investor clients.** *Shareholders should contact the firm immediately as there may be limited time to enforce your rights.* **Why Your Participation Matters:** As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. *Your investment. Your voice. Your future.*™ For additional information, please visit Shareholder Derivative Litigation - Kuehn Law. Attorney advertising. Prior results do not guarantee similar outcomes. Contacts: Kuehn Law, PLLC Justin Kuehn, Esq. 53 Hill Street, Suite 605 Southampton, NY 11968 justin@kuehn.law (833) 672-0814 SOURCE Kuehn Law, PLLC ### Related Stocks - [RGNX.US](https://longbridge.com/en/quote/RGNX.US.md) ## Related News & Research - [RegenXBio Faces RGX-121 Clinical Hold, Refocuses Pipeline](https://longbridge.com/en/news/296834397.md) - [FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome](https://longbridge.com/en/news/296779641.md) - [Tribe Property Technologies Inc. reports Q2 results](https://longbridge.com/en/news/296953133.md) - [REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli | RGNX Stock News](https://longbridge.com/en/news/296903302.md) - [REGENXBIO elects Gregory Ciongoli as director; Jean Bennett and. "Jerry" Karabelas resign](https://longbridge.com/en/news/296955594.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**